EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 286 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... April 26, 2022 The digital shift: How are remote GP appointments affecting cancer patients? December 17, 2021 Study Suggests that Cancer Patients Who Eat Peanuts Frequently May Be... August 5, 2021 6-Yr-Old With Cerebral Palsy Receives Dream Gift After Learning To Walk. January 9, 2020 Load more HOT NEWS When Ellen Found Out There Was A Grieving Mother In The... Coverage for Breast Cancer Genetic Marker Testing is Still Being Denied... Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... Meteorologist Uses Sign Language To Tell All Of Her Weather Forecasts
